New: Introducing the Finviz Futures Map

Cognition Therapeutics, Inc.

Contributing Author

Recent Articles by Cognition Therapeutics, Inc.

Sep-03	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target CGTX GlobeNewswire
Sep-02	Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) CGTX GlobeNewswire
Aug-27	Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock CGTX GlobeNewswire
Aug-26	Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement CGTX GlobeNewswire
Aug-12	Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease CGTX GlobeNewswire
Aug-07	Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs CGTX GlobeNewswire
Jul-29	Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease CGTX GlobeNewswire
Jul-21	Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease CGTX GlobeNewswire
Jul-16	Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC CGTX GlobeNewswire
Jul-10	Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease CGTX GlobeNewswire
Jul-01	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target CGTX GlobeNewswire
Jun-25	Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB) CGTX GlobeNewswire
Jun-03	Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies CGTX GlobeNewswire
May-28	Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies CGTX GlobeNewswire
May-09	Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health CGTX GlobeNewswire
May-08	Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy CGTX GlobeNewswire
May-07	Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update CGTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.